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ABSTRACT:
Our recent research identified the protein annexin A2 to be regulated by ovarian 
cancer-peritoneal cell interactions. This study investigated the role of annexin A2 in 
ovarian cancer metastasis and its potential utility as a novel therapeutic target, using 
in vitro and in vivo ovarian cancer models. Annexin A2 expression was examined by 
qRT-PCR and western blotting in ovarian cancer cell lines and immunohistochemistry 
in serous ovarian carcinoma tissues. Annexin A2 siRNAs were used to evaluate the 
effects of annexin A2 suppression on ovarian cancer cell adhesion, motility, and 
invasion. Furthermore, annexin A2 neutralizing antibodies were used to examine 
the role of annexin A2 in tumor invasion and metastasis in vivo using a chick 
chorioallantoic membrane assay and an intraperitoneal xenograft mouse model. 
Strong annexin A2 immunostaining was observed in 90% (38/42) of the serous 
ovarian cancer cells and was significantly increased in the cancer-associated stroma 
compared to non-malignant ovarian tissues. Annexin A2 siRNA significantly inhibited 
the motility and invasion of serous ovarian cancer cells and adhesion to the peritoneal 
cells. Annexin A2 neutralizing antibodies significantly inhibited OV-90 cell motility 
and invasion in vitro and in vivo using the chick chorioallantoic membrane assay. 
The growth of SKOV-3 cells and their peritoneal dissemination in nude mice was 
significantly inhibited by annexin A2 neutralizing antibodies. Annexin A2 plays a 
critical role in ovarian cancer metastasis and is therefore a potential novel therapeutic 
target against ovarian cancer.
INTRODUCTION
Ovarian cancer is the most lethal gynecological 
cancer and ranks as the fifth most common cause of 
cancer-related death in women in the western world. It 
has been estimated that there will be 22,240 new cases of 
ovarian cancer and 14,030 deaths due to ovarian cancer 
in the United States in 2013 [1]. Despite improvements 
in the surgical treatment and the development of new 
chemotherapeutic agents over the last 10 years, ovarian 
cancer survival rates have not changed significantly. An 
increase of the ovarian cancer survival rate will require 
the successful development of more effective molecularly 
targeted therapies. 
Ovarian cancer has a distinct predisposition for 
metastasizing via shedding of cancerous cells from the 
ovary into the peritoneal cavity and implanting onto the 
peritoneum that lines the pelvic organs. Once ovarian 
cancer cells adhere to the peritoneal cells, they migrate 
through the peritoneal layer and invade local organs. The 
Oncotarget 2013; 4: 1199-12111200www.impactjournals.com/oncotarget
local invasion of organs, such as the bowel, eventually 
results in the death of the patient.
Our group has recently explored the interactions 
between ovarian cancer-peritoneal cells using an in vitro 
co-culture system [2]. One of the proteins identified by 2D 
gel electrophoresis and mass spectrometry to be regulated 
by ovarian cancer-peritoneal cell interactions was annexin 
A2 [3].
Annexin A2 is a multifunctional calcium 
phospholipid binding protein which binds to collagen I, 
cathepsin B and tenascin-C [4], assists in maintaining the 
plasticity and rearrangement of the actin cytoskeleton [5] 
and a cellular redox regulatory protein [6]. Annexin A2 
also plays an important role in the plasminogen activation 
system and acts as a tissue plasminogen activator (t-PA) 
receptor on the cell surface of endothelial and cancer 
cells, which mediates the conversion of plasminogen into 
plasmin [7, 8].
Various studies have found increased annexin A2 
tissue levels in malignancies of the breast, pancreas, 
oropharynx, liver, kidney, and bowel (reviewed by [3]). 
Annexin A2 has been shown to promote cell invasion 
in malignancies of the breast, brain, liver, and pancreas 
[9-12] and enhances cell motility and cell adhesion of 
prostate and hepatocellular carcinoma cells [12, 13]. 
However, the knowledge on the role of annexin A2 in 
ovarian cancer is very limited. It was identified to be 
upregulated in ovarian cancer cell lines with high invasive 
capacity compared to those with low invasive properties 
[14]. Moreover, a large scale proteomic study identified 
annexin A2 to be upregulated in ovarian cancers when 
compared with normal ovarian tissue and benign lesions 
[15]. This study investigated annexin A2 expression in 
serous ovarian cancer tissues and cell lines and performed 
functional in vitro and in vivo studies to examine its role 
in ovarian cancer cell adhesion, motility, invasion and 
metastasis.
RESULTS
Expression of annexin A2 in human ovarian 
cancer tissues and peritoneal cells 
Immunohistochemistry results showed positive 
immunostaining of annexin A2 in the epithelial cells 
of the normal surface epithelium (Fig. 1A), serous 
cystadenomas (Fig. 1B) and serous borderline ovarian 
tumors (Fig. 1C). In serous ovarian cancer cells, 
annexin A2 immunostaining was present predominantly 
in the membrane and cytoplasm but high annexin A2 
immunostaining was also noted in the cancer associated 
stroma (Fig. 1D). Strong annexin A2 immunostaining 
was observed in the peritoneal cells of the omentum 
(Fig. 1E) and in the peritoneal cells adjacent to ovarian 
cancer cells in the omentum (Fig. 1F). No staining was 
observed in the absence of the primary antibody (insert, 
Fig. 1A). Stromal annexin A2 immunostaining in the 
invasive serous ovarian carcinomas (stage I to IV) was 
significantly increased compared with normal ovaries, 
serous cystadenomas, or serous borderline tumors (P < 
0.0001). No difference was observed between the intensity 
of the annexin A2 immunostaining in the cancer cells (P 
= 0.510) or percentage of annexin A2 positive cancer 
cells (P = 0.248) between the different patients groups 
(Supplementary Table 1). No difference in annexin A2 
immunostaining was observed between primary tumor and 
matching omental metastasis tissues (Supplementary Table 
2). However, in metastatic omental implants, a higher 
proportion of ovarian cancer cells immediately adjacent 
to the peritoneal cells were annexin A2 positive (8/9) 
compared to ovarian cancers cells at a greater distance 
from the peritoneum (4/9) (P = 0.046, Pearson Chi Square) 
(Supplementary Table 3).
Expression of annexin A2 in human ovarian 
cancer and peritoneal cell lines
Real-time PCR results showed annexin A2 was 
expressed in human serous ovarian cancer cell lines 
(OVCAR-3, OVCAR-5, SKOV-3 and OV-90) and the 
peritoneal cell line, LP-9 (Fig. 2A). This was supported 
by 1D-western immunoblotting in the cell lysates as an 
annexin A2 band at 37 kDa was observed in all cell lines 
(Fig. 2B). These findings confirm that annexin A2 is 
produced by both ovarian cancer cells and peritoneal cells.
Annexin A2 is cleaved in ovarian cancer and 
peritoneal cells co-culture 
Annexin A2 was found to be increased in the 
secretome of co-cultured OVCAR-5 and LP-9 cells 
using 2D gel electrophoresis and mass spectrometry [3]. 
Annexin A2 expression was further examined by western 
immunoblotting in the conditioned media (CM) from 
OVCAR-3, OVCAR-5, and SKOV-3 cells either cultured 
alone or in co-culture experiments with LP-9 cells after 
48 h. A 37 kDa annexin A2 band at low abundance 
was observed in the CM from OVCAR-3, OVCAR-5, 
and SKOV-3 cells. In the LP-9 CM, two distinct bands 
corresponding to annexin A2 at approximately 37 and 36 
kDa were observed. A shift in the 37 kDa band to a 35 
kDa form was observed when LP-9 cells were co-cultured 
with OVCAR-3, OVCAR-5 or SKOV3 cells (Fig. 2C). 
A similar finding was observed with OV-90 and LP-9 
cells (data not shown). Mass spectrometry of annexin 
A2 from the CM of the co-cultured OVCAR-5 and LP-9 
(n=4) did not identify any annexin A2 peptides in the 
N-terminal domain (Supplementary Fig. 1). 2D-western 
immunoblotting was performed to confirm the presence 
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of processed or cleaved annexin A2 in the co-cultured 
LP-9 and OVCAR-5 CM compared with LP-9 CM 
cultured alone (Fig. 2D). Multiple annexin A2 spots at 
37 kDa and 35 kDa and pI values ranging from 6 to 8 in 
the co-cultured OVCAR-5 and LP-9 CM compared with 
the CM of LP-9 cells alone were observed. This result is 
consistent with the annexin A2 processing observed in the 
1D-western immunoblotting.
Annexin A2 is cleaved by protease plasmin
Plasmin digestion experiment demonstrated that 
recombinant annexin A2 is cleaved by plasmin and 
annexin A2 cleavage was partially inhibited following 
treatment with α2-antiplasmin (Fig. 2E). To evaluate 
whether annexin A2 processing was mediated by other 
proteases, co-cultured OVCAR-5 and LP-9 cells were 
treated with MMP inhibitor, GM-6001, a broad spectrum 
protease inhibitor cocktail as well as plasmin inhibitors, 
ε-ACA and α2-antiplasmin. In the co-culture experiment, 
only α2-antiplasmin was able to partially block annexin 
A2 cleavage (Fig. 2F). The other inhibitors used in the 
co-culture experiment had no effect on annexin A2 
processing.
Annexin A2 promotes ovarian cancer motility and 
invasion and aids peritoneal adhesion of ovarian 
cancer cells
To determine whether annexin A2 promotes ovarian 
cancer metastasis, we examined the effects of knocking 
down annexin A2 expression on ovarian cancer cell 
adhesion to the peritoneal cells, motility, and invasion. 
Figure 1: Annexin A2 immunostaining in human ovarian tissues and omental tissues. Annexin A2 immunostaining is present 
in the epithelial cells of normal surface epithelium (A), serous cystadenomas (B) and serous borderline ovarian tumors (C). Annexin A2 
immunostaining is present in membrane and cytoplasm of ovarian cancer cells and cancer associated stroma of stage 3 serous ovarian 
cancer tissues (D). Annexin A2 immunostaining is observed in peritoneal cells of the omentum (E) and serous ovarian cancer cells located 
adjacent to the peritoneal cells in omental implants (F). Insert in (A) is the negative control with no primary antibody. Magnification bar = 
100 µm for all images.
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Real-time PCR results showed annexin A2 siRNAs 
effectively knocked down annexin A2 expression up 
to 70% compared with negative control siRNA and 
non-treated OVCAR-5 cells (Supplementary Fig. 2A). 
Moreover, the knockdown of annexin A2 expression 
with siRNA A into OVCAR-3, OVCAR-5, SKOV-3, and 
OV-90 cells were confirmed by western immunoblotting 
(Supplementary Fig. 2B). Annexin A2 siRNA treated 
OVCAR-5, OV-90, SKOV-3, and OVCAR-3 cells showed 
significantly decreased motility (OVCAR-5 (P = 0.0008), 
OV-90 (P < 0.0001), SKOV-3 (P < 0.0001) and OVCAR-3 
(P = 0.0069) and invasion (OVCAR-5 (P = 0.0047), OV-
90 (P = 0.0047), SKOV-3 (P < 0.0001) and OVCAR-3 (P 
= 0.0002), compared with cells treated with the negative 
control siRNA (Fig. 3A-D). Furthermore, annexin A2 
siRNA treated SKOV-3, OVCAR-5, and OV-90 cells 
had significantly decreased adhesion to LP-9 cells when 
compared with cells treated with negative control siRNA 
(Fig. 3A-C, OVCAR-5 (P = 0.0005), OV-90 (P < 0.0001), 
SKOV-3 (P < 0.0001)). However, there was no difference 
in the adhesion to the peritoneal cells in annexin A2 
siRNA treated OVCAR-3 cells (Fig. 3D, P = 0.9057). We 
also observed a significant decrease in OV-90 cell motility 
(P = 0.0016) and invasion (P = 0.0031) after treatment 
with annexin A2 neutralizing antibody, compared with the 
mouse IgG antibody (Fig. 4A). Treatment of OVCAR-5 
cells with annexin A2 neutralizing antibody also showed a 
significant decrease in cell motility and invasion compared 
with the mouse IgG antibody (data not shown).
Annexin A2 promotes ovarian cancer cell invasion 
in the chick chorioallantoic membrane model
Ovarian cancer cell invasion was assessed using 
the CAM (chick chorioallantoic membrane) assay. OV-
90 cells were mixed together with matrigel and placed 
onto the CAM of the chick embryos (Fig. 4B). To 
evaluate the effects of annexin A2 on ovarian cancer cell 
invasion in vivo, OV-90 cells were treated with the mouse 
IgG antibody and annexin A2 neutralizing antibody. 
Haematoxylin and eosin staining and pan-cytokeratin 
immunostaining of OV-90 cells treated with the mouse 
IgG antibody showed invasion of OV-90 cancer cells 
through the ectoderm into the mesoderm of the CAM and a 
Figure 2: Annexin A2 expression in ovarian cancer cell lines, peritoneal cell line and co-cultured ovarian cancer and 
peritoneal cells. (A) Annexin A2 expression in OV-90, SKOV-3, OVCAR-5, OVCAR-3 and LP-9 cell lines determined by real-time PCR 
and were assessed using 2-ΔΔCT quantitation method. Data represents triplicate determinations ± SEM from 2 independent experiments. (B) 
Western immunoblotting shows annexin A2 band at 37 kDa in cell lysates of OV-90, SKOV-3, OVCAR-5, OVCAR-3 and LP-9. β-actin 
was used as loading control. (C) Western immunoblotting shows two isoforms of annexin A2 at 37 kDa and 36 kDa bands in the conditioned 
media (CM) of LP-9 cells alone and a 35 kDa annexin A2 band present in the CM of co-cultured LP-9 and ovarian cancer cells. (D) 
2D-western immunoblotting showed multiple annexin A2 spots at 37 kDa in the CM of LP-9 cells alone and annexin A2 isoforms at 37 kDa 
and 35 kDa in the CM of co-cultured LP-9 and OVCAR-5 cells over a pI values range of 6 to 8. (E) Annexin A2 western immunoblotting 
of recombinant annexin A2 with GST tag (~63.4 kDa) and a cleaved annexin A2 at ~36 kDa in the presence of plasmin that was partially 
inhibited by α2-antiplasmin. (F) Annexin A2 western immunoblotting of the CM of co-cultured OVCAR-5 and LP-9 cells treated with α2-
antiplasmin, protease inhibitor cocktail, ε-aminocaproic acid (ε-ACA), GM-6001 and DMSO.
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destruction of the ectoderm layer (Fig. 4C,D). In contrast, 
OV-90 cells treated with annexin A2 neutralizing antibody 
exhibited minimal invasion through the ectoderm and 
mesoderm of the CAM (Fig. 4E,F). Quantitative analysis 
showed that annexin A2 antibody significantly inhibited 
OV-90 cancer cell invasion into the CAM mesoderm. 
Treatment with annexin A2 antibody resulted in a 3.6 fold 
reduction in cancer cell invasion, compared with OV-90 
cancer cells treated with mouse IgG antibody (Fig. 4G, P 
= 0.004, Mann-Whitney U test).
Annexin A2 promotes ovarian cancer growth and 
metastasis 
We utilized an intraperitoneal xenograft mouse 
model to assess the role of annexin A2 in ovarian cancer 
metastasis in vivo. The extensive tumor development and 
peritoneal metastasis observed with mouse IgG treatment 
(Fig. 5A) was significantly reduced in mice treated with 
annexin A2 neutralizing antibody (Fig. 5B). Tumor burden 
measured by bioluminescence was significantly reduced 
by annexin A2 neutralizing antibody treatment compared 
with mouse IgG antibody treatment over a 36 day period 
(Fig. 5C, Supplementary Fig. 3 and P < 0.05, Mann-
Whitney U test).
We investigated the possible mechanisms for 
the reduced tumor burden in the annexin A2 antibody 
treatment group by analysing tumor cell proliferation, 
cell apoptosis and angiogenesis. Neutralizing annexin 
A2 antibody had no effect on SKOV-3 cell proliferation 
(Ki67, Fig. 6A), but significantly increased SKOV-3 cell 
apoptosis (active caspase 3, Fig. 6B). No difference in 
vascular density was observed between the two treatment 
groups (CD34, Fig. 6C). Our findings suggest the reduced 
tumor burden and metastatic spread in the annexin 
A2 antibody treatment group is a result of reduced cell 
survival.
DISCUSSION
To our knowledge, this is the first study to investigate 
the role of annexin A2 in ovarian cancer invasion and 
metastasis. Here we show i) high annexin A2 expression 
in 90% of serous ovarian cells and increased annexin A2 
levels in the cancer-associated stroma, ii) suppression of 
annexin A2 expression significantly reduces migration and 
invasion of 4 ovarian cancer cell lines, iii) down regulation 
of annexin A2 reduces adhesion of ovarian cancer cells 
Figure 3: The effects of annexin A2 siRNA knockdown on ovarian cancer cell motility, invasion and adhesion in vitro. 
(A) OVCAR-5, (B) OV-90, (C) SKOV-3 and (D) OVCAR-3 cell motility, invasion and adhesion to the peritoneal cells after treatment with 
annexin A2 siRNA. Data are expressed as a percentage of the negative control siRNA, mean ± SEM of quadruplicates from 3 independent 
experiments (n=12). *, significantly different from control (P < 0.05, Student t- test).
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to the peritoneal cells, and iv) annexin A2 neutralizing 
antibodies blocks migration and invasion of ovarian 
cancer cells, both in vitro and in vivo. Collectively these 
results provide strong evidence that annexin A2 plays a 
pivotal role in ovarian cancer progression and metastasis.
Ovarian cancer cell implantation onto the peritoneal 
lining is a vital step in ovarian cancer metastasis. However, 
the mechanisms involved in this process are poorly 
Figure 4: Annexin A2 promotes OV-90 cell motility and invasion in vitro and in vivo. (A) Cell motility and invasion of OV-90 
cells treated with mouse IgG antibody or annexin A2 neutralizing antibody in vitro. Data are expressed as a percentage of control mouse 
IgG, mean ± SEM of quadruplicates from 3 independent experiments (n=12). *, significantly different from control (P < 0.05, Student 
t-test). (B) Chick chorioallantoic membrane (CAM) implanted with matrigel and OV-90 cancer cells (CMI) at day 14 of chick embryo 
development. The CAM layers ectoderm (ECT), mesoderm (MES) and endoderm (END) are evident. Haematoxylin and eosin and pan-
cytokeratin immunohistochemistry of the CAM implanted with OV-90 cells in the presence of mouse IgG antibody (C,D) and annexin A2 
neutralizing antibody (E,F). (G) Quantitative analysis of OV-90 cells invasion into the CAM. Data represents mean ± SEM from 72-80 
images (n=12 chick embryos per treatment group from 2 independent experiments). *, significantly different from control (P < 0.05, Mann-
Whitney U test). Magnification bar = 100 µm for all images.
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characterized. In this study, annexin A2 was regulated as 
a result of ovarian cancer and peritoneal cell interactions. 
Although annexin A2 over expression has been observed 
in various cancer types such as those of the pancreas [16], 
colorectal [17], breast [11, 18], prostate [13], liver [19] 
and brain [9, 20], to date, no information on the expression 
of annexin A2 in human ovarian cancer tissues and its 
functional role in ovarian cancer have been published.
Our immunohistochemical studies showed annexin 
A2 expression in both the membrane and cytoplasm of 
ovarian cancer cells, but high annexin A2 levels were also 
observed in the cancer associated stroma. Strong annexin 
A2 expression in stromal cells was observed for all clinical 
stages of human ovarian cancer (stage I to IV) compared 
with normal ovaries, serous cystadenomas and borderline 
ovarian tumors. Increased levels of annexin A2 were also 
present in ovarian cancer cells located adjacent to the 
peritoneal cells in the omental implants tissues.
Figure 5: Annexin A2 promotes growth and metastasis of SKOV-3 cells. Tumor burden of mice treated with mouse IgG antibody 
(A) or anti-annexin A2 antibody (B) on day 36 using IVIS imaging and at autopsy, with haematoxylin and eosin staining showing the 
tumor morphology. Images represent 1 sec acquisition time, and the photon emission transmitted from mice was captured and quantitated 
in photons/s/cm2/sr. (C) Tumor growth and metastasis measured by bioluminescence. Arrow indicates the time point of weekly antibody 
administration until day 36 (*P < 0.05, Mann-Whitney U test). Data represents mean ±SEM (n=5 mice per treatment group). Magnification 
bar = 100 µm for all images.
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Annexin A2 was shown to be expressed in human 
ovarian cancer and peritoneal cell lines. We observed a 
shift in the full length 37 kDa annexin A2 band to a 35 
kDa isoform in the CM of co-cultured ovarian cancer and 
peritoneal cells. Furthermore, peptide mass fingerprinting 
of the annexin A2 protein in the co-cultured CM failed 
to detect any peptides containing the first 30 amino acids 
of the N-terminal domain of annexin A2. These findings 
suggest that annexin A2 is cleaved at the N-terminal 
domain as a result of the ovarian cancer-peritoneal cell 
co-culture environment.
We investigated whether annexin A2 cleavage in 
the ovarian cancer peritoneal cell co-culture could be 
inhibited by specific proteases. Plasmin is one of the 
proteases at the cell surface involved in remodeling the 
tumor microenvironment [21]. We previously showed 
that plasmin was upregulated in the CM of co-cultured 
ovarian cancer and peritoneal cells [2]. Previous studies 
reported annexin A2 cleavage by plasmin at lysine 27 in 
the N-terminal domain in monocytes [22], and between 
lysine 307 and arginine 308 in the C-terminal domain 
in endothelial cells [23]. Annexin A2 is also cleaved by 
proteases such as glycogen synthase-3 [24] and MMP-
7 [25]. We confirmed that plasmin cleaved recombinant 
annexin A2 and we demonstrated that annexin A2 cleavage 
in co-cultured ovarian cancer and peritoneal cells could be 
partially blocked by α2-antiplasmin. 
Our findings suggest that the extracellular form of 
annexin A2 found in the cancer associated stroma in the 
ovarian cancer tissues may represent a cleaved secreted 
form of annexin A2, which may assist ovarian cancer 
progression and metastasis. Since annexin A2 lacks a 
signal peptide and is not secreted via the endoplasmic 
reticulum pathway, the mechanism that regulates annexin 
A2 secretion remains unknown. It has been reported 
previously that cleavage of annexin A2 at lysine 10 by 
MMP-7 can assist tumor invasion and metastasis of 
colorectal and breast cancer cell lines [25]. Moreover, 
annexin A2 isoforms and cleaved annexin A2 were 
observed in normal and squamous cell carcinoma tissues, 
confirmed by 2D-western immunoblotting [26]. However, 
further studies are required to investigate annexin A2 
cleavage mechanisms, the functional role of cleaved 
annexin A2 and post-translational modifications of 
Figure 6: Annexin A2 neutralizing antibodies increase apoptosis. Tumor sections of mice treated with mouse IgG and anti-
annexin A2 antibodies were immunostained with (A) Ki67, (B) cleaved caspase 3 and (C) CD34. Data represents the median from 10 
images per mice (n=6 for mouse IgG and n=5 for anti-annexin A2 treatment groups). *, significantly different from control (P < 0.05, 
Mann-Whitney U test). Magnification bar = 100 µm for all images.
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annexin A2 in ovarian cancer.
In this study, we have demonstrated that suppression 
of annexin A2 using siRNA decreased ovarian cancer cell 
adhesion to the peritoneal cells, cell motility, and invasion 
in vitro. These observations concur with previous studies 
demonstrating decreased cell motility and invasion in 
cancers of the pancreas [10, 27], breast [28], brain [9], 
liver [12] and prostate [29] following treatment with 
annexin A2 siRNA. Moreover, our study demonstrated 
annexin A2 plays a role in ovarian cancer cell adhesion to 
the peritoneal cells. Shiozawa et al. reported that annexin 
A2 has a role in regulating prostate cancer cell adhesion to 
osteoblasts and endothelial cells using annexin A2 siRNA 
[13]. Silencing of annexin A2 expression significantly 
reduced cell adhesion of hepatocellular carcinoma cells 
[12] and cell adhesion of myeloid cells to human and 
murine osteoblasts cells [30]. Braden et al. also reported 
that down-regulation of annexin A2 expression using 
polymeric nanoparticles in prostate cancer cell line inhibits 
tumor growth in nude mice [29]. Therefore, annexin A2 
contributes to cancer progression by enhancing cancer cell 
motility, invasion and adhesion.
The functional role of annexin A2 in ovarian cancer 
cell motility and invasion was also assessed using annexin 
A2 neutralizing antibody. We showed OV-90 cells treated 
with neutralizing annexin A2 antibody significantly 
decreased motility and invasion in vitro and invasion 
in vivo in the chick embryo CAM model. Annexin 
A2 neutralizing antibodies also significantly inhibited 
growth and metastasis of SKOV-3 cells in nude mice. 
Our finding are consistent with previous reports that have 
shown annexin A2 neutralizing antibodies to inhibit cell 
migration, invasion, and to block plasminogen activation 
of breast cancer cells [11] and monocytes [31] in vitro. 
Moreover, anti-annexin A2 antibodies have been shown 
to inhibit pancreatic cancer metastasis in a mouse model 
of pancreatic ductal adenocarcinoma [10] and to inhibit 
tumor growth in breast cancer and Lewis Lung Carcinoma 
xenograft mouse models [32, 33]. A significant reduction 
of glioma tumor growth and progression in the annexin A2 
knockout mice model associated with a decrease in cancer 
cell invasion, angiogenesis and proliferation has also been 
reported [9]. Tumor growth of fibrosarcoma (HT1080) 
and lung cancer (A459) cell lines in NOD-SCID mice 
has also been shown to be inhibited following annexin A2 
depletion [6]. Furthermore, Zhai et al. showed a decrease 
in glioma tumor burden as a result of an increase in 
apoptosis in tumors of the annexin A2 knockout mice [9]. 
Similarly, we observed an increase in cell apoptosis, but 
no difference in the cell proliferation or vascular density 
in the tumor sections of mice with SKOV-3/GFP-Luc cells 
treated with anti-annexin A2 antibody. The in vivo findings 
from our CAM model and intraperitoneal xenograft mouse 
model were consistent with our in vitro observations 
demonstrating annexin A2 promotes ovarian cancer cell 
motility, invasion and tumor growth.
In conclusion, our findings demonstrate that annexin 
A2 plays an important role in ovarian cancer metastasis. 
Anti-annexin A2 antibodies significantly blocked ovarian 
cancer cell invasion in the CAM model and cancer cell 
peritoneal dissemination in the intraperitoneal xenograft 
mouse model. Annexin A2 is therefore a promising novel 
therapeutic target against ovarian cancer.
MATERIALS AND METHODS
Patient’s tissue samples
Archived formalin fixed paraffin tissue blocks from 
20 matching primary tumors and their metastatic implants, 
10 cases each of early stage serous ovarian cancer (stage 
I and II), advanced stage serous ovarian cancer (stage 
III and IV) and borderline ovarian tumors, 16 normal 
ovaries, 11 serous cystadenomas and 9 omental implants 
were obtained from the Institute of Medical Veterinary 
Science (SA Pathology), Adelaide, South Australia, 
Australia. Tissue microarrays (TMAs) were constructed 
from formalin-fixed, paraffin embedded tumor material 
with the approval from the Royal Adelaide Hospital ethics 
committee and each tissue block was represented by 
triplicate 1.0 mm diameter tissue cores.
Cell culture 
The human serous ovarian cancer cell lines 
OVCAR-3, SKOV-3 and OV-90 were purchased from 
American Type Culture Collection (ATCC, VA, USA). 
OVCAR-5 cells were obtained from Dr Thomas Hamilton 
(Fox Chase Cancer Center, PA, USA) and the peritoneal 
cells, LP-9 were purchased from Coriell Cell Repositories 
(NJ, USA). All cell lines were maintained as previously 
described [2]. The SKOV-3/GFP-Luc cells (Cell Biolabs 
Inc., CA, USA) were maintained in RPMI 1640 medium 
supplemented with 4mM L-glutamine, antibiotics (100 
U penicillin G, 100 µg/ml streptomycin sulfate and 0.25 
µg/ml amphotericin B) and supplemented with 5% fetal 
bovine serum (FBS) (Sigma-Aldrich, MO, USA). All cell 
lines were maintained at 37oC in an environment of 5% 
CO2.
Real-time PCR
Total RNA was extracted using TRIzol (Invitrogen, 
NSW, Australia) and each RNA sample was reverse 
transcribed using SuperScriptTM III Reverse Transcriptase 
(Invitrogen), as per manufacturer’s instructions. Real-
time PCR was performed in triplicates using human 
annexin A2 validated primers (QIAGEN, Australia) and 
SYBR Green PCR master mix (7900HT Fast Real-Time 
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PCR System, Applied Biosystems, NSW, Australia). The 
cycling parameters were: 50oC for 2 min, 95oC for 10 
min followed by 40 cycles of 95oC for 15 sec and then 
60oC for 1 min. The CT values were normalised relative 
to the housekeeping gene, L19 and were calibrated to the 
OVCAR-3 cells using the 2-(ΔΔCT) quantitation method.
Immunohistochemistry
For the annexin A2 immunohistochemistry, tissue 
sections (5 µm) underwent microwave antigen retrieval 
(5 min 750 W, 15 min 350 W) in 10 mM citric acid 
buffer (pH 6.5), and were incubated overnight with 
mouse monoclonal antibody to annexin A2 (1/500, BD 
Biosciences, CA, USA) in blocking buffer (5% normal 
goat serum) at 4°C. Visualization of immunoreactivity was 
achieved using biotinylated anti-mouse immunoglobulins 
(1/400, Dako, NSW, Australia), streptavidin-peroxidise 
conjugate (1/500, Dako) and diaminobenzidine 
tetrahydrochloride (DAB) (Sigma-Aldrich), as previously 
described [2]. Normal prostate tissue was used as a 
positive control [34] and negative controls included 
no primary antibody and mouse IgG controls. For the 
xenograft mouse model experiment, mouse tumor tissue 
sections were immunostained with active caspase-3 (rabbit 
polyclonal, 1/200, Cell Signaling Technology, MA, USA), 
Ki67 (rabbit monoclonal, 1/400, Epitomics, CA, USA) and 
CD34 (rat monoclonal, 1/100, clone MEC 14.7, Abcam, 
MA, USA), as previously described [35]. 
Co-culture of ovarian cancer and peritoneal cells 
LP-9 cells were cultured in 6 well plates until they 
reached confluency. OVCAR-5, SKOV-3, OV-90 and 
OVCAR-3 cells were added (2 x 105 cells/well) to the 
LP-9 monolayer and co-cultured in direct contact for 
48 h before the collection of the cell lysates and CM, as 
previously described [2]. OVCAR-5 and LP-9 cells were 
also co-cultured in the presence or absence of protease 
inhibitor cocktail (1/200, Sigma-Aldrich), MMP inhibitor, 
GM-6001 (20 µM, Calbiochem, CA, USA) as well as 
plasmin inhibitors, ε-ACA (150 mM, Sigma-Aldrich) and 
α2-antiplasmin (0.2 µM, Calbiochem). 
1D-western immunoblotting
Western immunoblotting was conducted as 
previously described [2] with a mouse monoclonal 
antibody to annexin A2 (1/2000, BD Biosciences) or 
β-actin antibody (1/2000, Abcam) and anti-mouse IgG 
peroxidase-conjugated secondary antibodies (1/2000, 
Dako). For the plasmin digestion, recombinant annexin 
A2 protein with a GST-tag (0.5 µg, Abnova, Taiwan) was 
incubated with plasmin (0.2 U/ml, Sigma-Aldrich) for 3 h 
at 37oC in the presence and absence of α2-antiplasmin (0.2 
µM, Calbiochem). 
2D-western immunoblotting
The total protein concentration of CM from LP-9 
alone and co-cultured OVCAR-5 and LP-9 was determined 
using EZQ protein assay (Invitrogen). The immobilized 
pH gradient (IPG) strips (11cm, GE Healthcare, NJ, 
USA) were rehydrated in rehydration buffer containing 
1.2% DeStreak, 0.5% C.A, 1% bromophenol blue and 
4% thiourea-urea-CHAPS (TUC) buffer overnight in 
IPGPhorII (GE Healthcare). A total of 50 µg protein 
sample was reduced with 1 M DTT, 0.8% IPG buffer, TUC 
buffer and bromophenol blue and applied to the IPG strip 
and isoelectric focusing was carried out using IPGPhorII at 
20oC as previously described [2]. Western immunoblotting 
was performed as per 1D-western immunoblotting.
Motility and invasion assays 
Cell motility and invasion assays were performed as 
previously described [36]. For the annexin A2 knockdown 
experiments, ovarian cancer cells were transfected with 
annexin A2 siRNAs (siRNA ID: s1384 (A) and s1385 
(B), 10 nM ) or negative siRNA (Ambion, TX, USA) with 
Oligofectamine (Invitrogen) for 48 h. Ovarian cancer 
cells were also pre-treated with annexin A2 neutralizing 
antibody (20 µg/ml, BD Biosciences) or mouse IgG 
antibody (20 µg/ml, Sigma-Aldrich) for 2 h. Cells were 
labelled with calcein-AM (1 µg/ml, Invitrogen) and 
were loaded onto uncoated 12 µm filter inserts (96-well 
plate, ChemoTx, Neuro Probe, MD, USA) for migration 
assays or 12 µm filters coated with Geltrex (0.6 µl/well, 
Invitrogen) for invasion assays. The cells were allowed 
to migrate and invade to the lower chamber for 6 h and 
the bottom fluorescence of migratory cells was measured 
at 485-520 nm using the Triad series multimode detector 
(Dynex Technologies, VA, USA).
Adhesion assay
Adhesion assay were performed as previously 
described [2]. Briefly, ovarian cancer cells were transfected 
with either annexin A2 siRNA A or negative siRNA for 
48 h and labelled with calcein-AM. Ovarian cancer cells 
were added to the LP-9 cell monolayer and were allowed 
to adhere for 8 min. The fluorescence of adhered cells was 
measured at 485-520 nm using the Triad series multimode 
detector (Dynex Technologies).
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Chick chorioallantoic membrane assay 
Fertilized white leghorn chicken eggs (Hi Chick, 
SA, Australia) were maintained at 37°C in 60% relative 
humidity in a Multiquip Incubator E2 (Multiquip Pty. 
Ltd., NSW Australia). Approval was obtained by the 
University of Adelaide Animal Ethics Committee. On 
day 3 of chick embryo development, a small opening 
was made under aseptic conditions in the egg shell. To 
investigate the effects of annexin A2 on ovarian cancer 
cell invasion in the CAM model, OV-90 cells (9x104 cells) 
were mixed with matrigel (8.9 mg/mL, BD Biosciences) 
with either annexin A2 neutralizing antibody (20 µg/
ml, BD Biosciences) or mouse IgG antibody (20 µg/ml, 
Sigma-Aldrich) in a total volume of 30 µl and placed on 
the CAM of day 11 chick embryos (n=6 chick embryos 
per treatment group). The invasion of the cancer cells 
through the ectoderm into the mesoderm was assessed 
on day 14 of chick embryo development in paraffin-
embedded CAM sections stained with haematoxylin, eosin 
and pan-cytokeratin immunohistochemistry, as previously 
described [37]. 
Intraperitoneal SKOV-3 xenograft mouse model
An intraperitoneal SKOV-3 xenograft non-invasive 
and whole-body bioluminescent imaging model was 
used with the approval obtained by the University of 
Adelaide Animal Ethics Committee. Nude mice were 
injected intraperitoneally with SKOV-3/GFP-Luc cells 
(1x108 cells/0.5ml) and were treated weekly with either 
100 µg mouse IgG antibody or 100 µg anti-annexin 
A2 antibodies (BD Biosciences). Mice were injected 
intraperitoneally with D-luciferin (Caliper Life Sciences, 
MA, USA) solution at 150 mg luciferin/kg body weight 
and then gas-anesthetized with isoflurane (Bomac Pty. 
Ltd., NSW, Australia). Precisely 10,15 and 20 min 
following D-luciferin injection, images were acquired for 
0.5 to 10 sec and the photon emission transmitted from 
mice was captured and quantitated in photons/s/cm2/sr 
using the IVIS Imaging System 100 (Xenogen Imaging 
Technology, CA, USA) with living image software (Igor 
Pro version 2.5). At autopsy, tumor tissues were fixed with 
4% paraformaldehyde (Sigma-Aldrich) and embedded into 
paraffin blocks. 
Immunohistochemical assessment
Slides were digitally scanned using the NanoZoomer 
(Hamamatsu Photonics, Japan) and images were 
captured using NDP view imaging software (Hamamatsu 
Photonics). The immunostaining intensity of annexin A2 
in the epithelial and stromal compartments was assessed 
using a manual scoring method: strong (3+), moderate 
(2+), weak (1+), or negative (0). A score of 0 or 1+ was 
defined as low annexin A2 immunostaining and a score or 
2+ or 3+ was defined as high annexin A2 immunostaining. 
The percentage of annexin A2 positive cancer cells were 
independently assessed in the ovarian cancer tissues. 
For the CAM assay, quantitative analysis to assess OV-
90 cancer cell invasion was performed on 8 to 12 CAM 
images for each embryo as previously described [37]. For 
the mouse tumor tissue sections, ten random images of 
each tissue were captured at 40x magnification for Ki67 
and activated caspase-3 and at 20x magnification for 
CD34. Colour threshold detection by the AnalySIS-ProTM 
software (Soft Imaging System, Germany) was used to 
determine positive (brown pixels) and negative (purple 
pixels) stained cells. Data was expressed as percentage of 
positive pixels (positive brown stained divided by negative 
purple stained area) for Ki67 and percentage of positive 
CD34 pixels of the total tumor area. For active caspase 
3, the number of positive cells in ten fields were counted 
manually and expressed as a percentage of the total tumor 
area. The mouse treatment groups were blinded until 
completion of all analyses.
Statistical analysis
All statistical analyses were performed using SPSS 
19.0 for Windows (SPSS Inc., IL, USA). The Chi-Square 
test was used to determine statistical significance between 
annexin A2 immunostaining in the ovarian and omental 
tissue groups. The Student’s t-test and one-way ANOVA 
with Dunnett C or Dunnett T post-hoc tests were used 
to determine statistical significance between control and 
treatment groups. For the CAM assay and xenograft 
mouse model experiments, the Mann-Whitney U test was 
used to determine the significance between control and 
treatment groups. Statistical significance was accepted at 
P < 0.05.
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